UNASSIGNED: @entity69610 is an intermediate in the manufacture of @entity24740 dyes. In a National Toxicology Program stop-exposure study, @entity69610 induced @entity1373 , @entity1185 , and @entity1377 in the urinary bladder of Fischer 344/ @entity35 . @entity69610 was investigated since occupational or environmental exposure to @entity9308 and @entity24740 dyes is a risk factor for @entity150 in @entity1 . The current study describes the morphology of @entity150 seen in @entity35 with respect to those observed in @entity1 . This study also evaluated immunohistochemical expression of the cell cycle-related proteins @entity12003 and @entity10740 and the differentiation markers @entity61118 and uroplakin III in @entity5072 (n = 11) and neoplastic (n = 6 @entity1185 , n = 11 @entity189 ) lesions of the urinary bladder epithelium from @entity35 treated with @entity69610 and in normal (n = 6) urinary bladders from untreated @entity35 . The @entity5 observed were more similar to the papillary type rather than the muscle-invasive type of @entity150 in @entity1 . The preneoplastic and neoplastic lesions observed suggest progression from @entity1373 to @entity1185 to @entity1377 . With @entity5 ( @entity1373 to @entity189 ), @entity12003 immunoreactivity progressively increased in intensity, percentage of cells staining, and distribution. Overexpression of @entity10740 was not found. @entity61118 staining decreased in superficial cells, while uroplakin III staining increased in intermediate and basal cells with progression from @entity1373 to @entity189 . The results are consistent with increased cell cycle dysregulation or proliferation ( @entity12003 ), decreased differentiation ( @entity61118 ), and abnormal differentiation (uroplakin III) as lesions progress toward @entity5 .

Immunohistochemical Expression of XXXX , @entity61118 , and Uroplakin III in Proliferative Urinary Bladder Lesions Induced by @entity69610 in Fischer 344/ @entity35 .

@entity1 :: ('9606', 'Species') :: ['humans'] @entity1377 :: ('MESH:D002291', 'Disease') :: ['papillary carcinomas', 'papillary carcinoma'] @entity10740 :: ('301300(Tax:10116)', 'Gene') :: ['p53'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors', 'neoplastic progression', 'malignancy'] @entity24740 :: ('CHEBI:33835', 'Chemical') :: ['azo'] @entity1373 :: ('MESH:D006965', 'Disease') :: ['hyperplasia'] @entity1185 :: ('MESH:D010212', 'Disease') :: ['papillomas', 'papilloma'] @entity5072 :: ('MESH:D000796', 'Disease') :: ['hyperplastic'] @entity12003 :: ('58919(Tax:10116)', 'Gene') :: ['cyclin D1'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas', 'carcinoma', 'papilloma to carcinoma'] @entity61118 :: ('286912(Tax:10116)', 'Gene') :: ['cytokeratin 20', 'Cytokeratin 20'] @entity150 :: ('MESH:D001749', 'Disease') :: ['urinary bladder cancer', 'urinary bladder neoplasms'] @entity9308 :: ('MESH:C023650', 'Chemical') :: ['aniline'] @entity35 :: ('10116', 'Species') :: ['N rats', 'rats'] @entity69610 :: ('MESH:C005328', 'Chemical') :: ['o-Nitroanisole', 'o-nitroanisole']
@entity12003 :: (58919(Tax:10116),Gene) :: ['Cyclin D1']
